BioDelivery Sciences International, Inc. (BDSI) Given Average Recommendation of “Buy” by Brokerages

Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) have earned a consensus recommendation of “Buy” from the nine research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $4.57.

Several research analysts have recently commented on the stock. Roth Capital set a $5.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a report on Thursday, October 12th. Seaport Global Securities assumed coverage on shares of BioDelivery Sciences International in a report on Friday. They set a “buy” rating and a $5.00 target price on the stock. HC Wainwright set a $5.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a report on Friday, October 13th. Piper Jaffray Companies set a $4.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a report on Sunday, October 22nd. Finally, Cantor Fitzgerald set a $5.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a report on Thursday, October 12th.

BioDelivery Sciences International (BDSI) traded down $0.10 during trading on Tuesday, reaching $2.45. 795,311 shares of the company’s stock traded hands, compared to its average volume of 573,466. The company has a market cap of $131.55, a PE ratio of 27.22 and a beta of 0.74. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.07 and a current ratio of 1.28. BioDelivery Sciences International has a 52-week low of $1.55 and a 52-week high of $3.60.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. BioDelivery Sciences International had a net margin of 10.40% and a return on equity of 33.83%. The company had revenue of $11.25 million for the quarter, compared to analysts’ expectations of $9.40 million. During the same period last year, the firm earned ($0.30) earnings per share. The business’s revenue for the quarter was up 215.1% on a year-over-year basis. equities analysts forecast that BioDelivery Sciences International will post 0.16 EPS for the current year.

In related news, Director Mark A. Sirgo sold 162,509 shares of the stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $2.78, for a total transaction of $451,775.02. Following the sale, the director now owns 1,759,262 shares in the company, valued at approximately $4,890,748.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark A. Sirgo sold 108,000 shares of the stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $2.57, for a total transaction of $277,560.00. Following the sale, the director now owns 1,759,262 shares in the company, valued at approximately $4,521,303.34. The disclosure for this sale can be found here. Insiders have sold a total of 980,011 shares of company stock worth $2,666,275 in the last quarter. 9.00% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN boosted its position in shares of BioDelivery Sciences International by 138.2% during the 3rd quarter. Wells Fargo & Company MN now owns 35,506 shares of the specialty pharmaceutical company’s stock worth $105,000 after acquiring an additional 20,599 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of BioDelivery Sciences International during the 3rd quarter worth approximately $116,000. Advisor Group Inc. boosted its position in shares of BioDelivery Sciences International by 42.1% during the 2nd quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock worth $126,000 after acquiring an additional 13,341 shares in the last quarter. Krilogy Financial LLC boosted its position in shares of BioDelivery Sciences International by 28.8% during the 3rd quarter. Krilogy Financial LLC now owns 134,000 shares of the specialty pharmaceutical company’s stock worth $395,000 after acquiring an additional 30,000 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of BioDelivery Sciences International by 0.9% during the 2nd quarter. Northern Trust Corp now owns 140,450 shares of the specialty pharmaceutical company’s stock worth $394,000 after acquiring an additional 1,203 shares in the last quarter. Institutional investors and hedge funds own 44.25% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.com-unik.info/2018/01/28/biodelivery-sciences-international-inc-bdsi-given-average-recommendation-of-buy-by-brokerages.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit